141 related articles for article (PubMed ID: 15472905)
1. Reduced metastasis of transgenic mammary cancer in urokinase-deficient mice.
Almholt K; Lund LR; Rygaard J; Nielsen BS; Danø K; Rømer J; Johnsen M
Int J Cancer; 2005 Feb; 113(4):525-32. PubMed ID: 15472905
[TBL] [Abstract][Full Text] [Related]
2. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice.
Almholt K; Nielsen BS; Frandsen TL; Brünner N; Danø K; Johnsen M
Oncogene; 2003 Jul; 22(28):4389-97. PubMed ID: 12853975
[TBL] [Abstract][Full Text] [Related]
3. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
4. Reduced metastasis of Polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice.
Bugge TH; Lund LR; Kombrinck KK; Nielsen BS; Holmbäck K; Drew AF; Flick MJ; Witte DP; Danø K; Degen JL
Oncogene; 1998 Jun; 16(24):3097-104. PubMed ID: 9671388
[TBL] [Abstract][Full Text] [Related]
5. Spontaneous lung and lymph node metastasis in transgenic breast cancer is independent of the urokinase receptor uPAR.
Almholt K; Lærum OD; Nielsen BS; Lund IK; Lund LR; Rømer J; Jögi A
Clin Exp Metastasis; 2015 Aug; 32(6):543-54. PubMed ID: 26040548
[TBL] [Abstract][Full Text] [Related]
6. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer.
Vasiljeva O; Papazoglou A; Krüger A; Brodoefel H; Korovin M; Deussing J; Augustin N; Nielsen BS; Almholt K; Bogyo M; Peters C; Reinheckel T
Cancer Res; 2006 May; 66(10):5242-50. PubMed ID: 16707449
[TBL] [Abstract][Full Text] [Related]
7. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model.
Frandsen TL; Holst-Hansen C; Nielsen BS; Christensen IJ; Nyengaard JR; Carmeliet P; Brünner N
Cancer Res; 2001 Jan; 61(2):532-7. PubMed ID: 11212246
[TBL] [Abstract][Full Text] [Related]
8. Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model.
Almholt K; Juncker-Jensen A; Laerum OD; Danø K; Johnsen M; Lund LR; Rømer J
Mol Cancer Ther; 2008 Sep; 7(9):2758-67. PubMed ID: 18790756
[TBL] [Abstract][Full Text] [Related]
9. MEKK1 controls matrix degradation and tumor cell dissemination during metastasis of polyoma middle-T driven mammary cancer.
Cuevas BD; Winter-Vann AM; Johnson NL; Johnson GL
Oncogene; 2006 Aug; 25(36):4998-5010. PubMed ID: 16568086
[TBL] [Abstract][Full Text] [Related]
10. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals.
Shapiro RL; Duquette JG; Roses DF; Nunes I; Harris MN; Kamino H; Wilson EL; Rifkin DB
Cancer Res; 1996 Aug; 56(15):3597-604. PubMed ID: 8758932
[TBL] [Abstract][Full Text] [Related]
11. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
12. Pleiotropic functions of the tumor- and metastasis-suppressing matrix metalloproteinase-8 in mammary cancer in MMTV-PyMT transgenic mice.
Decock J; Hendrickx W; Thirkettle S; Gutiérrez-Fernández A; Robinson SD; Edwards DR
Breast Cancer Res; 2015 Mar; 17(1):38. PubMed ID: 25848906
[TBL] [Abstract][Full Text] [Related]
13. Long-term exposure to elevated levels of circulating TIMP-1 but not mammary TIMP-1 suppresses growth of mammary carcinomas in transgenic mice.
Yamazaki M; Akahane T; Buck T; Yoshiji H; Gomez DE; Schoeffner DJ; Okajima E; Harris SR; Bunce OR; Thorgeirsson SS; Thorgeirsson UP
Carcinogenesis; 2004 Sep; 25(9):1735-46. PubMed ID: 15166086
[TBL] [Abstract][Full Text] [Related]
14. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model.
Mitra SK; Lim ST; Chi A; Schlaepfer DD
Oncogene; 2006 Jul; 25(32):4429-40. PubMed ID: 16547501
[TBL] [Abstract][Full Text] [Related]
15. Deletion of Cd151 reduces mammary tumorigenesis in the MMTV/PyMT mouse model.
Roselli S; Kahl RG; Copeland BT; Naylor MJ; Weidenhofer J; Muller WJ; Ashman LK
BMC Cancer; 2014 Jul; 14():509. PubMed ID: 25012362
[TBL] [Abstract][Full Text] [Related]
16. Increased bone formation in mice lacking plasminogen activators.
Daci E; Everts V; Torrekens S; Van Herck E; Tigchelaar-Gutterr W; Bouillon R; Carmeliet G
J Bone Miner Res; 2003 Jul; 18(7):1167-76. PubMed ID: 12854826
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with verapamil, a calcium channel blocker, and B428, a synthetic uPA inhibitor, impairs the metastatic ability of a murine mammary carcinoma.
Todaro LB; Ladeda V; Bal de Kier Joffé E; Farías EF
Oncol Rep; 2003; 10(3):725-32. PubMed ID: 12684650
[TBL] [Abstract][Full Text] [Related]
18. Transgenic expression of human cathepsin B promotes progression and metastasis of polyoma-middle-T-induced breast cancer in mice.
Sevenich L; Werner F; Gajda M; Schurigt U; Sieber C; Müller S; Follo M; Peters C; Reinheckel T
Oncogene; 2011 Jan; 30(1):54-64. PubMed ID: 20818432
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of the metastasis of Lewis lung carcinoma by antibody against urokinase-type plasminogen activator in the experimental and spontaneous metastasis model.
Kobayashi H; Gotoh J; Shinohara H; Moniwa N; Terao T
Thromb Haemost; 1994 Apr; 71(4):474-80. PubMed ID: 8052966
[TBL] [Abstract][Full Text] [Related]
20. Coordinated and cell-specific induction of both physiological plasminogen activators creates functionally redundant mechanisms for plasmin formation during ovulation.
Hägglund AC; Ny A; Liu K; Ny T
Endocrinology; 1996 Dec; 137(12):5671-7. PubMed ID: 8940398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
